Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …

Background Proactive recommendations for human papillomavirus (HPV) vaccines in Japan
have been suspended for 5 years because of safety concerns. While no scientific evidence …

Background Emerging observational evidence suggests a single-dose of human
papillomavirus (HPV) vaccine may be protective against vaccine-targeted HPV infection and …

Background. Effectiveness of human papillomavirus (HPV) vaccines in the context of both
guidelines, which recommend vaccination at 14 years and modest vaccine coverage, is …

Background Benign or malignant lesions caused by Human papillomavirus (HPV) produce
considerable health burden worldwide. Since limited cross-protection would be offered …

Background Continued surveillance of human papillomavirus (HPV) vaccination is
necessary to identify clinical benefits, particularly given the low rate of vaccine uptake and …

BACKGROUND: Two HPV vaccines prevent infection with HPV-16 and HPV-18, high-risk
(cancer-associated) HPV types which together cause approximately 70% of cervical …

To assess the pattern of multiple human papillomavirus infection to predict the type
replacement postvaccination. A total of 7372 women aged 18–45y from a phase III trial of an …

Human papillomavirus (HPV) infection is a major cause of cervical cancer. HPV vaccine has
been shown to be highly effective in preventing HPV infection, and understanding the …

Background: Previous studies have demonstrated racial and ethnic differences in the
distribution of human papillomavirus (HPV) types among adult women with cervical …